Did you catch it Ted-? About 10:40 it took off-- (without me) VCI Global Limited (VCIG) NasdaqCM - NasdaqCM Real Time Price. 7.25+4.42 (+156.18%)<---------------- At close: 04:00PM EDT
VCI Global To Distribute AI-Based State Of The Art “Socializer Messenger” For Cogia GmbH VCI Global Limited Tue, June 20, 2023, 7:28 AM EDT In this article: VCIG +156.18% VCI Global Limited KUALA LUMPUR, Malaysia, June 20, 2023 (GLOBE NEWSWIRE) -- VCI Global Limited (NASDAQ: VCIG) (“VCI Global”, or the “Company”) announced it has been appointed by Cogia GmbH as the latter’s distributor for the promotion and sale of its communication application known as “Socializer Messenger”. The “Socializer Messenger” is a game changing, complete communication suite. On top of the basic conventional services being offered by other messaging devices, this AI-based, military grade messenger elevates communications to four additional dimensions namely privacy, security, business and administration. In short, it is a secured all-in-one communication tool with full data encryption and privacy protection. “Socializer Messenger” is owned and controlled by Cogia GmbH, a software company based in Germany, with extensive experience in software development, in AI, text mining, web monitoring and cyber security. VCIG is granted an exclusive distributorship within the Southeast Asian countries and non-exclusive distributorship for areas outside Southeast Asia to, amongst others, promote, market and distribute this messenger. For its role, VCIG shall be entitled to a percentage of the revenue generated from the sales of the messenger. Once formalised, this distributorship is for a period of two years and will automatically be renewed for an additional year. “Humbled would not truly describe our appreciation to Cogia as we offer our vast networking platform to Cogia to tap into for the distribution of its communication application, in particularly, to this part of the region. This (distributorship) will open up yet another revenue stream for us which will undoubtedly increase VCI Global’s value,” said Dato’ Victor Hoo, Group Executive Chairman and Chief Executive Officer of VCI Global. "We are excited to leverage on VCI Global's expertise and extensive network to establish a strong presence, provide tailored AI and secure communication solutions to meet the evolving needs of the Southeast Asian markets," said Pascal Lauria, Founder and Chief Executive Officer of Cogia GmbH.
It is with great humility I unveil THE CHINA WATCH LIST: While other names were in distress this found buyers today.... 1> CBAK Energy Technology, Inc. (CBAT) @$1.35 NasdaqCM - NasdaqCM Real Time Price. 1.3500+0.0200 (+1.50%) At close: 04:00PM EDT
Posted on the wrong thread again. My fault. We'll let the rest go tomorrow. Factory Opening play they usualy work! PureCycle Technologies shares jump after Ironton plant reports first resin production Jun. 20, 2023 5:41 PM ET PureCycle Technologies, Inc. (PCT) PureCycle Technologies (NASDAQ:PCT) said Tuesday it successfully produced the first run of Ultra-Pure Recycled (UPR) resin from post-industrial recycled material at its Ironton plant in Ohio. Once fully operational, the Ironton facility is projected to have an annual production capacity of 107 million pounds of UPR resin. Shares +10.5% at $8.77 after hours.<-------
Hello friends- Thank you for advice on Jeep. A week from Monday she goes to the station where she'll sit for ages before they repair it. My China WIMI hologram continues to get out and about China. Everyone is very nice. This si the country that wants to kill us? Take over Taiwan> Everyone is so nice and they all want to hear about Pickelball. Small racket loud noise I tell them. My Hologram roams the streets- and can time shift year to year.
Bill Gates’ venture firm, with backing from Jeff Bezos and Jack Ma, just minted a $1 billion A.I. unicorn that uses machine learning for mining rare earth metals crucial for EVs Tue, June 20, 2023, 10:55 AM EDT KoBold Metals, a Berkeley-based mining company that uses artificial intelligence to mine for rare earth elements, has closed out a funding round that crowns it an A.I. “unicorn” worth $1 billion and ropes in some of the biggest investors in the world. The $200 million round, reported in the Wall Street Journal, included money from Breakthrough Energy Ventures, a Bill Gates–backed venture capital firm that invests in clean energy companies on behalf of people including Jeff Bezos and Jack Ma. Other investors included the massively influential VC firm Andreessen Horowitz and Bond Capital, cofounded by Mary Meeker, a longtime VC known for spotting big-picture trends early and whose annual Internet Trends Report is one of the most highly anticipated among tech investors. The raise brings KoBold’s valuation to more than $1 billion. The company’s last funding round raised $192.5 million in February 2022. Breakthrough Energy Ventures and Bond were both part of that earlier round. KoBold, founded in 2018, uses machine learning to look for deposits of metals that are crucial to the construction of batteries for electric vehicles—specifically lithium, nickel, cobalt, and copper. The company has more than 60 projects across three continents, in which it is currently investing $100 million annually. It also has an extensive research and development budget devoted to A.I.’s use in modeling the earth’s subsurface and exploring depths beyond the reach of conventional techniques. “Our proprietary A.I. tools build on a concept we call efficacy of information (EOI), enabl[ing] KoBold to determine which data to collect at each exploration step, to maximize uncertainty reduction,” the company said on its website. It might take longer to reach the metals, but the drilling will be precision-focused, the company says. The recent purchase of a copper deposit in Zambia, for example, is expected to take eight years to yield results. Demand for lithium, nickel, cobalt, and copper is on the rise. By 2050, KoBold predicts, there will be a $12 trillion gap between supply and demand. This story was originally featured on Fortune.com
DICE scored GBA a 2nd round of gains-! Try that home kids. I alwayd said DICE would be bought and it was- This Co also has that feel. Research Drug Stock Poised For Growth With Record Sales, Strong Outlook Licensing 02:13 PM ET 06/20/2023 Intra-Cellular Therapies (ITCI) is finding support at the 21-day moving average in a flat base. The buy point is 66.56. The growth stock is in the IBD 50 list of stocks with strong fundamental and technical ratings and matching price performance. The early-stage base-on-base pattern has a depth of 12%, according to IBD MarketSmith chart analysis. The growth stock has a stellar record of sales increases over the past seven quarters. Sales have grown at a compounded rate of 55% over the past 10 years and ranged from 120% to a staggering 950% from previous year quarters. Sales of $95.3 million grew an impressive 172% in the fiscal first quarter, though the loss per share of 46 cents shows that the company has yet to become profitable. Its drug Caplyta accounted for almost all sales, with total prescriptions increasing 159%. ITCI stock rose after results and broke out on May 1 as part of a five day-winning streak before starting the new base. Analysts polled by FactSet expect a steeper loss of 60 cents per share for the June quarter on sales of $106 million. For fiscal 2023, the company expects sales of Caplyta to be around $430 million to $455 million. Growth Stock Surges On Positive Results for Lumateperone Intra-Cellular shares surged on March 28 after the New York company announced positive results at week 6 for it double-blinded placebo-controlled randomized study of its drug Lumateperone to treat depressive and bipolar disorders with mixed features. Mixed features — which include depressive symptoms during a manic phase and vice versa — have been the more difficult to treat. For high-growth companies, cash position is a key data point to watch. ITCI ended with $541 million in cash for the first quarter, compared with $594 million a year ago. ITCI stock has an adequate Composite Rating of 89 and an RS Rating of 90. The stock has gained 22% so far this year. It trades at a price-to-sales ratio of 19.6, according to FactSet. It is in the highly ranked medical biomedical group, which sits at No. 21 in IBD's 197 industry groups. Intra-Cellular specializes in small molecule drug treatments for neurological diseases, such as Alzheimer's, by targeting intracellular signals in the central nervous system. Its chief drug, Caplyta, is approved for treating schizophrenia and conditions associated with bipolar disorder in adults. The drug is used as a primary treatment or in combination with lithium or FDA-approved drugs to treat mixed-features disorders.